Get the Stockscreener App
0.8068
3.95%
-0.0332
After Hours:
.81
0.0032
+0.40%
Indaptus Therapeutics Inc stock is traded at $0.8068, with a volume of 29,086.
It is down -3.95% in the last 24 hours and up +3.05% over the past month.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.
See More
Previous Close:
$0.84
Open:
$0.822
24h Volume:
29,086
Relative Volume:
1.32
Market Cap:
$9.69M
Revenue:
-
Net Income/Loss:
$-15.42M
P/E Ratio:
-0.4385
EPS:
-1.84
Net Cash Flow:
$-13.41M
1W Performance:
-0.40%
1M Performance:
+3.05%
6M Performance:
-46.57%
1Y Performance:
-59.66%
1-Day Range:
$0.7497
$0.85
1-Week Range:
$0.7497
$0.86
52-Week Range:
$0.7012
$3.10
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
0.8068 | 9.69M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
INDAPTUS THERAPEUTICS Earnings Results: $INDP Reports Quarterly Earnings - Nasdaq
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update - The Manila Times
Indaptus Therapeutics reports full-year loss of $1.61 per share -March 13, 2025 at 07:40 am EDT - Marketscreener.com
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results - TradingView
Indaptus Therapeutics Enrolls Over 20 Patients in Phase 1 Trial of Decoy20, Achieving Key Clinical Milestone - Nasdaq
Indaptus Therapeutics, Inc. SEC 10-K Report - TradingView
Indaptus Advances Cancer Trial With 20+ Patients, Strengthens Financial Position With $20M Backup - StockTitan
Registration Is Now Open For Tribe Public's Webinar Event 'Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 - The Manila Times
Registration Is Now Open For Tribe Public’s Webinar Event - GlobeNewswire
Revolutionary Immune System Technology Unveiled: Indaptus CEO to Share Groundbreaking Insights - StockTitan
Indaptus Therapeutics extends patent portfolio in China, Japan, and Israel - BSA bureau
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Indaptus Therapeutics Expands Patent Portfolio In China, Japan, And Israel, Strengthening Its Intellectual Property For Infectious Disease And Cancer Treatments - Marketscreener.com
Indaptus secures new patents in Asia and Israel for Decoy platform By Investing.com - Investing.com South Africa
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments - The Manila Times
Indaptus secures new patents in Asia and Israel for Decoy platform - Investing.com
Indaptus Therapeutics Secures New Patent Approvals in China, Japan, and Israel for Decoy Platform in HIV and HBV Treatment - Nasdaq
Can Indaptus' New Asian Patents Transform Its Position in the $4B Hepatitis B Market? - StockTitan
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - The Manila Times
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit - StockTitan
Indaptus Therapeutics (NASDAQ:INDP) Trading Down 0.6% – Should You Sell? - Defense World
Indaptus Therapeutics Enters Standby Equity Purchase Deal With YA II PN -February 12, 2025 at 12:30 pm EST - Marketscreener.com
Indaptus Therapeutics Enters Equity Purchase Agreement With Ya II Pn -February 12, 2025 at 09:29 am EST - Marketscreener.com
Indaptus Therapeutics expands cancer trial to Canada - Investing.com India
Indaptus Therapeutics Files Prospectus Relating To Proposed Resale By Selling Stockholders Of Up To 4.4 Million Shares - Marketscreener.com
Indaptus Therapeutics Expands Decoy20 Clinical Trial To Canada - Nasdaq
Indaptus Therapeutics expands cancer trial to Canada By Investing.com - Investing.com South Africa
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 - The Manila Times
Major Clinical Trial Expansion: Indaptus' Cancer Immunotherapy Decoy20 Gets Canadian Green Light - StockTitan
Head-To-Head Contrast: Indaptus Therapeutics (NASDAQ:INDP) vs. Biofrontera (NASDAQ:BFRI) - Defense World
Indaptus Therapeutics Receives Notification from Nasdaq Regarding Minimum Bid Price RequirementUnited States Securities and Exchange Commission, Washington, DC 20549Form 8-KIndaptus Therapeutics, Inc. recently received a notification from Nasda - Defense World
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus Therapeutics Announces $2.25 Million Private Placement - Defense World
Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in funding - Marketscreener.com
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Indaptus Therapeutics Secures $2.25M Private Placement for R&D Advancement - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - The Manila Times
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - GlobeNewswire Inc.
Indaptus Therapeutics (NASDAQ:INDP) Trading Up 6.3% – Still a Buy? - Defense World
INDP stock touches 52-week low at $0.81 amid market challenges - Investing.com Canada
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Indaptus Therapeutics files to sell 1.94M shares of common stock - MSN
Indaptus Therapeutics (NASDAQ:INDP) Shares Down 1% – Here’s Why - Defense World
Gram-negative bacteria platform offers multiple immune receptor agonists for tumor immunotherapy - BioWorld Online
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Indaptus Therapeutics announces $2.135M registered direct offering - MSN
Indaptus secures $2.1 million through stock and warrants sale By Investing.com - Investing.com Canada
Indaptus secures $2.1 million through stock and warrants sale - Investing.com India
Indaptus Therapeutics Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - citybiz
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - The Manila Times
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):